Ocugen, Inc. (NASDAQ:OCGN) in recent session today was buoying at a rise of 0.85% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $0.6 and 5Y monthly beta was reading 2.85 with its price kept floating in the range of $0.5913 and $0.6480 on the day. Company’s P/E ratio for the trailing 12 months is 0.29. Considering stock’s 52-week price range provides that OCGN hit a high price of $17.4 and saw its price falling to a low level of $0.17 during that period. Over a period of past 1-month, stock came adding 204.74% in its value.
With its current market valuation of $67.62 Million, Ocugen, Inc. is set to declare its quarterly results on August 14, 2020. OCGN Stock’s Forward Dividend of 0 and its yield of 0 are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.03 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.16 for 2020 with estimates of that growing to -$0.14 in next year. These estimates are suggesting current year growth of -0.87% for EPS and -0.13% growth next year.
In contrast, when we review OCGN stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Buy for it.
In comparing Ocugen, Inc. (OCGN)’s stock with other industry players reveals that stock’s latest price change of +0.85% and that of -94.74% over the past 12 months is in competing position with that of Bristol-Myers Squibb Company (BMY) which saw its stock price fell by -0.97% in the recent trading and went through an increase of 36.89% in past 12-month trading. Industry’s another major player Amgen Inc (AMGN) has fell -0.53% down in latest trading session, but over the past year has faced a rise of 17.27%, while Gilead Sciences Inc (GILD) is also up 0.85% however its price remained floating in the red at -94.74% over the same period. Ocugen, Inc. has a P/E ratio of 0.29 against that of Bristol-Myers Squibb Company’s 0 while Amgen Inc is showing 19.75 for the same. On the other hand, the S&P 500 Index was up 0.11% in the early deals while the Dow Jones Industrial was dealing lower at -0.19%.
Having a second look at Ocugen, Inc. (NASDAQ:OCGN) provides that stock’s average daily trading volume for 3 months was 34.21 Million, while it jumped to 35.3 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock currently stood at 135.01 Million.
Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 8.15% while it is 11.98% for the institutional holders. The figures also indicate that as of July 30, 2020, number of stock’s short shares was 6600000 which implies a short ratio of 0.11. This shows up a 4.89% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short declined as it was 325.12 Million in the previous month. Addition of +14.98% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.